DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Information source: Loyola University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Multiple Myeloma

Intervention: Bendamustine (Drug); Bortezomib (Drug); Lenalidomide (Drug); Dexamethasone (Drug)

Phase: Phase 1/Phase 2

Status: Recruiting

Sponsored by: Loyola University

Official(s) and/or principal investigator(s):
Laura Michaelis, MD, Principal Investigator, Affiliation: Loyola Univ Med Cntr - Cardinal Bernardin Cancer Cntr

Overall contact:
Laura Michaelis, MD, Phone: 708-327-3216, Email: lmichaelis@lumc.edu


The purpose of the study is to determine the safety and efficacy of the use of Bendamustine in combination with a commonly used combination chemotherapy to treat relapsed and refractory multiple myeloma. The study will be conducted in two phases. Participants in phase I will receive 1 of 4 escalating doses of bendamustine. Once the maximum tolerated dose of bendamustine is determined phase II of this trial will begin. Participants in phase II will receive the maximum tolerated dose of bendamustine in combination with standard of care chemotherapy.

Clinical Details

Official title: An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Maximally Tolerated Dose of Bendamustine

Secondary outcome:

Drug Toxicity


Response Rates

Detailed description: Multiple myeloma is a multi-organ neoplastic disorder caused by the clonal proliferation of plasma cells. It has an incidence of about 4. 5/100,000 per year in the U. S., making it the second most common hematologic malignancy. For many years, alkylating agents have been the backbone of treatment. The combination of melphalan and prednisone was, for many years, the standard of care for patients who were not candidates for autologous transplantation. Melphalan continues to be the primary conditioning agent for autologous transplant,and cyclophosphamide has also gained a foothold in the treatment of this disease. The introduction of novel agents has fundamentally changed the landscape of treating this disease, although the true effects on survival are not yet known. Immunomodulatory agents and proteosome inhibitors, including thalidomide, lenalidomide and bortezomib, have been used in both newly diagnosed and relapsed patients. Currently, there is intense clinical research on the optimal way to combine these novel agents with the traditional backbones of

treatment - including alkylators, with one another and, eventually, with the subsequent

iterations of these classes of drugs. However, despite the therapeutic excitement surrounding this disease, nearly all patients will relapse, and cure remains an elusive goal for all but a rare handful.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Adults with relapsed and/or refractory myeloma who have received between 1-4 prior

lines of therapy

- must have adequate liver and renal function

- ZPS of 2 or better

- must have measurable disease

Exclusion Criteria:

- Peripheral neuropathy of grade II or higher

- Thrombocytopenia (platelets less than 50,000/uL)

- Neutropenia (ANC<1000/uL)

- AST or ALT >2. 4 X ULN

- Total bilirubin >1. 5 X ULN

- Creatinine clearance of less than 60mL/min (Phase I) and of 40mL/min or less (Phase


- Patients with HIV

- Patients with active hepatitis

- Pregnant or lactating women

- Individuals of child-bearing potential not using adequate contraception

- Individuals unable to provide informed consent

Locations and Contacts

Laura Michaelis, MD, Phone: 708-327-3216, Email: lmichaelis@lumc.edu

Loyola Univ Med Cntr - Cardinal Bernardin Cancer Center, Maywood, Illinois 60153, United States; Recruiting
Laura Michaelis, MD, Phone: 708-327-3216, Email: lmichaelis@lumc.edu
Michelle Deutsch, RN, Phone: 708-327-3022, Email: mdeutsc@lumc.edu
Laura Michaelis, MD, Principal Investigator
Additional Information

Starting date: May 2011
Last updated: October 29, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017